Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Quantum Dots Could Supercharge Antibiotic Treatments

By Ryan Bushey | October 5, 2017

Engineers may have found a new way to boost the effectiveness of antibiotics to combat the spread of resistant superbugs.

Researchers from the University of Colorado at Boulder found that quantum dots, a series of light-activated nanoparticles, can interfere with important processes performed by bacteria making them more susceptible to the original antibiotic.

The team introduced these nano-engineered quantum dots to certain clinical isolate infections where they can be deployed selectively and activated or de-activated using specific wavelengths of light.

The dots differ from previous antibiotic treatments because they are able to work selectively on an intracellular level. They are small enough to slip inside and help clear the infection from within.

“We’ve developed a one-two knockout punch,” said co-lead study author and assistant professor in CU Boulder’s Department of Chemical and Biological Engineering (CHBE) Prashant Nagpal, in a statement. “The bacteria’s natural fight reaction [to the dots] actually leaves it more vulnerable.”

A chemical called superoxide is released by these molecules, which ends up interfering with the bacterium’s metabolic and cellular processes reducing the effective antibiotic resistance of the isolate infections by a factor of 1,000 without inducing adverse side effects.

“We are thinking more like the bug,” said another co-lead author of the study Anushree Chatterjee, an assistant professor in CHBE, in a statement. “This is a novel strategy that plays against the infection’s normal strength and catalyzes the antibiotic instead.”

Ultimately, the researchers feel the biggest advantage of this quantum dot technology is that it gives clinicians a flexible multipronged approach to fighting infections that are already straining the limits of current treatments.

Findings from this research were published in the journal Science Advances.


Filed Under: Drug Discovery

 

Related Articles Read More >

EpicentRx
A next-gen vaccine that could help end COVID-19 whack-a-mole 
Dotmatics
How Dotmatics aims to help reduce the drug discovery failure rate
Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50